What a New Study on FSHD and Mortality Means for Our Community
by Amanda Hill, Research & Care Programs Officer at the FSHD Society, and Ally Roets, Parent, Caregiver, CureFSHD for All Advocate and Parents’ Roundtable Leader Many of us in […]
Now available. Read our 2025 Impact Report
by Amanda Hill, Research & Care Programs Officer at the FSHD Society, and Ally Roets, Parent, Caregiver, CureFSHD for All Advocate and Parents’ Roundtable Leader Many of us in […]
Press release originally posted to the MDA website on Jan. 27, 2026 Organizations Join Forces to Map How Human Muscle Regenerates Muscular Dystrophy Association-led research collaboration with FSHD Society, LGMD2L […]
January 12, 2026, Originally posted to Business Wire Highlights: Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children […]
Nov. 26, 2025 Exciting news this week: Altay Therapeutics’ DX5057 has received Orphan Drug status from the U.S. FDA. DX5057 is currently the only oral DUX4 inhibitor in development for […]
− Primer paciente con distrofia muscular facioescapulohumeral (FSHD) tratado con células progenitoras modificadas del revestimiento umbilical (UMPC) de Restem-L. − El estudio de fase 1/2a evaluará la seguridad y la eficacia preliminar de […]